Dermoscopy Image Assessment Based on Perceptible Color Regions

2015 ◽  
pp. 247-262 ◽  
Keyword(s):  
2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii301-iii301
Author(s):  
Sidnei Epelman ◽  
Vijay Ramaswamy ◽  
Ethel Gorender ◽  
Luis Henrique Sakamoto

Abstract BACKGROUND Long-term survival in diffuse intrinsic pontine glioma is rare, and typically associated with atypical imaging and/or atypical clinical course. Although most patients harbor hotspot mutations in H3.1/3-K27M, a proportion of patients have alternate mutations, despite a typical clinicoradiological course. Herein we describe a long-term survivor with a classical presentation, treated with nimotuzumab, highlighting the challenges associated with such cases. CASE REPORT: A 5 year old male, diagnose in 2012 with a 10 day history multiple cranial neuropathies and a right hemiparesis. Cranial MRI revealed a poorly delimited diffuse pontine tumor and secondary hydrocephalus. Tumor biopsy was not performed due to the classic clinical presentation, and he received 54Gy/30 of radiation plus concomitant weekly nimotuzumab 150mg/m2. Initial tumor dimensions were 43x31x28mm. Nimotuzumab 150mg/m2 was continued every 2 weeks. Image assessment at week 12 of treatment revealed 16.9% volume increase, 4 weeks after radiotherapy completion. Nevertheless, subsequent neuroimaging at 24th, 36th, 60th, 96th and 108th weeks of nimotuzumab therapy showed a sustained and progressive tumor cytoreduction of 47.5%, 59%, 62.2%, 63.8% and 67%, respectively, when compared with post-radiotherapy dimensions. Currently, the patient is 13y old, good school performance, no neurologic disabilities. The last MRI at 394 weeks of nimotuzumab revealed dimensions of 21x19x14mm which corresponds to 70% of reduction compared with initial volume. CONCLUSIONS Our case of progressive cytoreduction over two years of a classic DIPG, diagnosed in the era prior to the discovery of the K27M mutation, highlights the challenges associated with long-term survival of this devastating entity.


2021 ◽  
Author(s):  
Méryem-Maud Farhat ◽  
Pierre Guerreschi ◽  
Sandrine Morell-Dubois ◽  
Valérie Deken ◽  
Julien Labreuche ◽  
...  

Abstract Background: Systemic sclerosis (SSc) is a fibrotic disease. Assessment of body image could be central in optimizing care. Yet, data are scarce. The main objective was to assess perception of aesthetic impairment using a visual aesthetic scale (AES) in patients with SSc compared to healthy subjects. Secondary objectives were to assess associations between perception of aesthetic impairment and standardized questionnaires for aesthetic impairment as well as clinical, psychological/quality of life, and functional parameters of SSc. Methods: This study evaluated and compared perception of aesthetic impairment in two populations: patients with SSc, in a referral center at Lille Hospital, France, and healthy controls. Results: This study included 88 patients (69 [78.4%] women) with a median age of 52 years and 88 controls (49 [55.7%] women) with a median age of 45 years. Perception of aesthetic impairment assessed using the AES was poorer in patients than in controls (3.7 ± 0.3 vs 2.8 ± 0.3, p=0.028), with statistical correlation with ASWAP. Patients with anxiety or depressive symptoms had significantly higher AES scores. Conclusion: The AES appears to be an ease of use tool to evaluate body image. Correlations found with psychological and quality of life parameters reflect the importance of these parameters for body image evaluation and its complex assessment.Trials registration: NCT03271320


1989 ◽  
Author(s):  
Donald A. Williamson ◽  
C. J. Davis ◽  
Anthony J. Goreczny ◽  
David C. Blouin
Keyword(s):  

2010 ◽  
Vol 26 (4) ◽  
pp. 301-304 ◽  
Author(s):  
Guillermo M. Pérez ◽  
Salomé Abenza ◽  
Alvaro De Casas ◽  
Jose M. Marín ◽  
Pablo Artal

2015 ◽  
Vol 76 (01) ◽  
pp. e91-e97 ◽  
Author(s):  
Giulia Serra ◽  
Athanasios Koukopoulos ◽  
Lavinia De Chiara ◽  
Alexia E. Koukopoulos ◽  
Leonardo Tondo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document